Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trial

Cristiana Sessa, Giorgio Bolis, Nicoletta Colombo, Maurizio D'Incalci, Bernadette Mermillod, Ivana Valente, Costantino Mangioni

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

After stratification according to diameter of the largest residual tumor, 120 previously untreated ovarian cancer patients were randomized to receive adriamycin and cyclophosphamide in combination with hexamethylmelamine (HAC) or cis-dichlorodiamineplatinum (PAC). The surgical response rates were 66% to HAC and 70% to PAC, with median times to progression of 14 and 22 months and median survival times of 23 and 24 months, respectively. In patients with residual tumor >2 cm the surgical response rates to HAC and PAC were 56% and 63%, with complete response rates of 13% and 21%, respectively. In two of five complete responders to HAC there has still been no progression at 38 and 48 months, with a median response duration of 25 months. Only one of the nine complete responders to PAC has relapsed, at 33 months, while in the eight others response is maintained at follow-up times of 35-64 months. Myelosuppression was generally mild and similar in the two arms. No significant nonhematological toxicity was reported. It is concluded that at a median follow-up time of 36 months HAC is as effective as PAC in terms of response, duration of remission, and survival in previously untreated advanced ovarian cancer.

Original languageEnglish
Pages (from-to)222-228
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume14
Issue number3
DOIs
Publication statusPublished - Apr 1985

Fingerprint

Altretamine
Ovarian Neoplasms
Doxorubicin
Cyclophosphamide
Randomized Controlled Trials
Residual Neoplasm
Tumors
Survival
Toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer : A randomized clinical trial. / Sessa, Cristiana; Bolis, Giorgio; Colombo, Nicoletta; D'Incalci, Maurizio; Mermillod, Bernadette; Valente, Ivana; Mangioni, Costantino.

In: Cancer Chemotherapy and Pharmacology, Vol. 14, No. 3, 04.1985, p. 222-228.

Research output: Contribution to journalArticle

@article{a1f9239bf3334c4192292b063c0a2133,
title = "Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trial",
abstract = "After stratification according to diameter of the largest residual tumor, 120 previously untreated ovarian cancer patients were randomized to receive adriamycin and cyclophosphamide in combination with hexamethylmelamine (HAC) or cis-dichlorodiamineplatinum (PAC). The surgical response rates were 66{\%} to HAC and 70{\%} to PAC, with median times to progression of 14 and 22 months and median survival times of 23 and 24 months, respectively. In patients with residual tumor >2 cm the surgical response rates to HAC and PAC were 56{\%} and 63{\%}, with complete response rates of 13{\%} and 21{\%}, respectively. In two of five complete responders to HAC there has still been no progression at 38 and 48 months, with a median response duration of 25 months. Only one of the nine complete responders to PAC has relapsed, at 33 months, while in the eight others response is maintained at follow-up times of 35-64 months. Myelosuppression was generally mild and similar in the two arms. No significant nonhematological toxicity was reported. It is concluded that at a median follow-up time of 36 months HAC is as effective as PAC in terms of response, duration of remission, and survival in previously untreated advanced ovarian cancer.",
author = "Cristiana Sessa and Giorgio Bolis and Nicoletta Colombo and Maurizio D'Incalci and Bernadette Mermillod and Ivana Valente and Costantino Mangioni",
year = "1985",
month = "4",
doi = "10.1007/BF00258120",
language = "English",
volume = "14",
pages = "222--228",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer

T2 - A randomized clinical trial

AU - Sessa, Cristiana

AU - Bolis, Giorgio

AU - Colombo, Nicoletta

AU - D'Incalci, Maurizio

AU - Mermillod, Bernadette

AU - Valente, Ivana

AU - Mangioni, Costantino

PY - 1985/4

Y1 - 1985/4

N2 - After stratification according to diameter of the largest residual tumor, 120 previously untreated ovarian cancer patients were randomized to receive adriamycin and cyclophosphamide in combination with hexamethylmelamine (HAC) or cis-dichlorodiamineplatinum (PAC). The surgical response rates were 66% to HAC and 70% to PAC, with median times to progression of 14 and 22 months and median survival times of 23 and 24 months, respectively. In patients with residual tumor >2 cm the surgical response rates to HAC and PAC were 56% and 63%, with complete response rates of 13% and 21%, respectively. In two of five complete responders to HAC there has still been no progression at 38 and 48 months, with a median response duration of 25 months. Only one of the nine complete responders to PAC has relapsed, at 33 months, while in the eight others response is maintained at follow-up times of 35-64 months. Myelosuppression was generally mild and similar in the two arms. No significant nonhematological toxicity was reported. It is concluded that at a median follow-up time of 36 months HAC is as effective as PAC in terms of response, duration of remission, and survival in previously untreated advanced ovarian cancer.

AB - After stratification according to diameter of the largest residual tumor, 120 previously untreated ovarian cancer patients were randomized to receive adriamycin and cyclophosphamide in combination with hexamethylmelamine (HAC) or cis-dichlorodiamineplatinum (PAC). The surgical response rates were 66% to HAC and 70% to PAC, with median times to progression of 14 and 22 months and median survival times of 23 and 24 months, respectively. In patients with residual tumor >2 cm the surgical response rates to HAC and PAC were 56% and 63%, with complete response rates of 13% and 21%, respectively. In two of five complete responders to HAC there has still been no progression at 38 and 48 months, with a median response duration of 25 months. Only one of the nine complete responders to PAC has relapsed, at 33 months, while in the eight others response is maintained at follow-up times of 35-64 months. Myelosuppression was generally mild and similar in the two arms. No significant nonhematological toxicity was reported. It is concluded that at a median follow-up time of 36 months HAC is as effective as PAC in terms of response, duration of remission, and survival in previously untreated advanced ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021913998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021913998&partnerID=8YFLogxK

U2 - 10.1007/BF00258120

DO - 10.1007/BF00258120

M3 - Article

C2 - 3922639

AN - SCOPUS:0021913998

VL - 14

SP - 222

EP - 228

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -